# ![@JCO_ASCO Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::2395900849.png) @JCO_ASCO Journal of Clinical Oncology

Journal of Clinical Oncology posts on X about stage, in the, editor, factor the most. They currently have [------] followers and [---] posts still getting attention that total [--] engagements in the last [--] hours.

### Engagements: undefined [#](/creator/twitter::2395900849/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2395900849/c:line/m:interactions.svg)

- [--] Week [-----] +21%
- [--] Month [-----] +54%
- [--] Months [------] +8.20%
- [--] Year [------] +179%

### Mentions: undefined [#](/creator/twitter::2395900849/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2395900849/c:line/m:posts_active.svg)


### Followers: [------] [#](/creator/twitter::2395900849/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2395900849/c:line/m:followers.svg)

- [--] Week [------] +0.09%
- [--] Month [------] +0.33%
- [--] Months [------] +2.10%
- [--] Year [------] +5.60%

### CreatorRank: undefined [#](/creator/twitter::2395900849/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::2395900849/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[finance](/list/finance)  1.98% [social networks](/list/social-networks)  0.99% [technology brands](/list/technology-brands)  0.99%

**Social topic influence**
[stage](/topic/stage) 4.95%, [in the](/topic/in-the) 4.95%, [editor](/topic/editor) 4.95%, [factor](/topic/factor) 3.96%, [events](/topic/events) 3.96%, [history](/topic/history) 2.97%, [dr](/topic/dr) 2.97%, [the new](/topic/the-new) 1.98%, [superior](/topic/superior) 1.98%, [financial](/topic/financial) 1.98%

**Top accounts mentioned or mentioned by**
[@asco](/creator/undefined) [@guptaarjun90](/creator/undefined) [@diegoadiazg](/creator/undefined) [@drrishabhonco](/creator/undefined) [@medwatchkate](/creator/undefined) [@astroorg](/creator/undefined) [@drjfriedberg](/creator/undefined) [@ascoguideline](/creator/undefined) [@ascos](/creator/undefined) [@pamelakunzmd](/creator/undefined) [@atlpedshemonc](/creator/undefined) [@ascopost](/creator/undefined) [@doctorpemm](/creator/undefined) [@drchoueiri](/creator/undefined) [@amerurological](/creator/undefined) [@andreanecchi](/creator/undefined) [@danafarbernews](/creator/undefined) [@crukcamaero](/creator/undefined) [@socsurgonc](/creator/undefined) [@drdonsdizoninvites](/creator/undefined)

**Top assets mentioned**
[Frontline Ltd. (FRO)](/topic/$fro)
### Top Social Posts
Top posts by engagements in the last [--] hours

"Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2Positive Breast Cancer. Read the full article. #BreastCancer #bcsm https://brnw.ch/21wZTso https://brnw.ch/21wZTso"  
[X Link](https://x.com/JCO_ASCO/status/2021993505808109579)  2026-02-12T17:03Z 55.4K followers, [----] engagements


"Baseline use of [--] mg or more of prednisone associated with worse outcomes in NSCLC patients treated with PD-L1 blockade #immunoonc #lcsm http://bit.ly/2BCI1Ml http://bit.ly/2BCI1Ml"  
[X Link](https://x.com/JCO_ASCO/status/1033082810532339712)  2018-08-24T20:05Z 55.4K followers, [---] engagements


"A new guideline from @ASTRO_org @ASCO & @AmerUrological: Hypofractionated radiotherapy for localized prostate cancer #pcsm #radonc http://bit.ly/2PBh26d http://bit.ly/2PBh26d"  
[X Link](https://x.com/JCO_ASCO/status/1052956253264195584)  2018-10-18T16:15Z 55.4K followers, [--] engagements


"Read Now: Pembrolizumab and Radical Cystectomy in Urothelial Bladder Cancer simultaneously published with poster discussion session by @AndreaNecchi at #ESMO18 http://bit.ly/2pXIKyZ http://bit.ly/2pXIKyZ"  
[X Link](https://x.com/JCO_ASCO/status/1053634384983715840)  2018-10-20T13:09Z 55.4K followers, [--] engagements


"Identification of incidental germline mutations in patients with advanced cancer who underwent circulating tumor cfDNA sequencing http://bit.ly/2R82Pht http://bit.ly/2R82Pht"  
[X Link](https://x.com/JCO_ASCO/status/1055535769945886721)  2018-10-25T19:05Z 55.4K followers, [--] engagements


"Longer follow-up confirms RFS benefit with adjuvant dabrafenib + trametinib in BRAF V600-mutant stage III melanoma #melsm http://bit.ly/2R8wPcY http://bit.ly/2R8wPcY"  
[X Link](https://x.com/JCO_ASCO/status/1055825164615798784)  2018-10-26T14:15Z 55.4K followers, [--] engagements


"CD19 CAR T-cell therapy for refractory aggressive B-cell lymphoma #immunoonc #lymsm http://bit.ly/2Btuqng http://bit.ly/2Btuqng"  
[X Link](https://x.com/JCO_ASCO/status/1075070709003665414)  2018-12-18T16:50Z 55.4K followers, [--] engagements


"Updated analysis of KEYNOTE-024 - pembrolizumab vs platinum-based chemo for advanced NSCLC #lcsm #immunoonc http://bit.ly/2LUcZ3W http://bit.ly/2LUcZ3W"  
[X Link](https://x.com/JCO_ASCO/status/1083430854192492544)  2019-01-10T18:30Z 55.4K followers, [---] engagements


"RECIST was developed and validated for evaluation of tumor responses to chemotherapy. Does it also work well for response assessment of targeted cancer agents http://bit.ly/2UxtypI http://bit.ly/2UxtypI"  
[X Link](https://x.com/JCO_ASCO/status/1105844732268343297)  2019-03-13T14:55Z 55.4K followers, [--] engagements


"New #JCOCCI special collection examines field of mathematical oncology #mathonc http://bit.ly/2ZwpWr1 http://bit.ly/2ZwpWr1"  
[X Link](https://x.com/JCO_ASCO/status/1121161061326032896)  2019-04-24T21:16Z 55.4K followers, [--] engagements


"JCO [----] Impact Factor has risen to [------] the highest in the history of the Journal http://bit.ly/2UKyfjh http://bit.ly/2UKyfjh"  
[X Link](https://x.com/JCO_ASCO/status/1141748816087015425)  2019-06-20T16:45Z 55.4K followers, [---] engagements


"The DNA damage repair (DDR) pathway as a target for novel drugs in gynecologic cancers #gyncsm http://bit.ly/2OYGFSw http://bit.ly/2OYGFSw"  
[X Link](https://x.com/JCO_ASCO/status/1163887195624804352)  2019-08-20T18:55Z 55.4K followers, [---] engagements


"Greater physical activity associated with longer progression-free survival and reduced risk of grade 3+ treatment-related toxicities in metastatic colorectal cancer #crcsm @DanaFarberNews http://bit.ly/2P5m0MW http://bit.ly/2P5m0MW"  
[X Link](https://x.com/JCO_ASCO/status/1164611976946966528)  2019-08-22T18:55Z 55.4K followers, [--] engagements


"Patients with mismatch repair-deficient stomach cancer may not benefit from perioperative or adjuvant chemotherapy results from [--] international randomised trials #stcsm @CRUKCamAero http://bit.ly/2mleOy7 http://bit.ly/2mleOy7"  
[X Link](https://x.com/JCO_ASCO/status/1174395186895605762)  2019-09-18T18:50Z 55.4K followers, [---] engagements


"Patients who were taking vitaminD supplements when initiating immune checkpoint inhibitor therapy had significantly reduced odds of developing ICIrelated colitis. #ASCODailyNews #ImmunoOnc20 http://bit.ly/2V78For http://bit.ly/2V78For"  
[X Link](https://x.com/JCO_ASCO/status/1231625023514959876)  2020-02-23T17:01Z 55.4K followers, [---] engagements


"Management of hereditary breast cancer - A new guideline from @ASCO @ASTRO_org @SocSurgOnc #bcsm #JCO https://fal.cn/37Ic6 https://fal.cn/37Ic6"  
[X Link](https://x.com/JCO_ASCO/status/1253322996057403392)  2020-04-23T14:01Z 55.4K followers, [--] engagements


"Breast cancer: [--] years of research & progress #bcsm #JCO https://fal.cn/37KOd https://fal.cn/37KOd"  
[X Link](https://x.com/JCO_ASCO/status/1254410469118484481)  2020-04-26T14:02Z 55.4K followers, [---] engagements


"#ASCOEdBook 📖 Editor in Chief @drdonsdizoninvites you to access [----] Ed Book articles for free at http://asco.org/edbook http://asco.org/edbook"  
[X Link](https://x.com/JCO_ASCO/status/1258773738302169088)  2020-05-08T15:00Z 55.4K followers, [---] engagements


"Tucatinib plus trastuzumab and capecitabine for patients with recurrent HER2-positive breast cancer with brain mets #bcsm #JCO https://fal.cn/38BMq https://fal.cn/38BMq"  
[X Link](https://x.com/JCO_ASCO/status/1271919785677393922)  2020-06-13T21:38Z 55.4K followers, [--] engagements


"#JCO's [----] impact factor rose to [------] the highest in the history of the Journal and placing it in the top 1% of all journals https://fal.cn/3940T https://fal.cn/3940T"  
[X Link](https://x.com/anyuser/status/1281197159145263104)  2020-07-09T12:03Z 55.4K followers, [--] engagements


"Dr. Jonathan W. Friedberg has been named the new editor in chief of #JCO with his five-year term beginning in June [----] @DrJFriedberg @WilmotCancer https://fal.cn/39nFe https://fal.cn/39nFe"  
[X Link](https://x.com/JCO_ASCO/status/1287760917455949832)  2020-07-27T14:45Z 55.4K followers, [---] engagements


"Management of aromatase inhibitor-induced musculoskeletal symptoms which can impact QOL and lead to premature medication discontinuation @guptaarjun90 et al #JCOOP #bcsm https://fal.cn/3a0Y1 https://fal.cn/3a0Y1"  
[X Link](https://x.com/JCO_ASCO/status/1299482152774533120)  2020-08-28T23:01Z 55.4K followers, [--] engagements


"FOLFOXIRI plus bevacizumab prolongs survival of patients with metastatic colorectal cancer - results of an individual patient data meta-analysis #crcsm #jco @ChiaraCrem1 https://fal.cn/3abJT https://fal.cn/3abJT"  
[X Link](https://x.com/JCO_ASCO/status/1303324728908800000)  2020-09-08T13:30Z 55.4K followers, [--] engagements


"#JCO Editorial: CDK 4/6 Inhibition in Early Stage Breast Cancer: The New Standard #ESMO20 #bcsm https://fal.cn/3ar41 https://fal.cn/3ar41"  
[X Link](https://x.com/JCO_ASCO/status/1307742825262522370)  2020-09-20T18:06Z 55.4K followers, [--] engagements


"Total neoadjuvant therapy for rectal cancer: Playing with dynamite A cautious assessment of TNT #crcsm #JCO https://fal.cn/3b8dw https://fal.cn/3b8dw"  
[X Link](https://x.com/JCO_ASCO/status/1319806820517597184)  2020-10-24T01:04Z 55.4K followers, [--] engagements


"Nasopharyngeal carcinoma is a unique head-and-neck cancer. This new @ASCO & CSCO Guideline addresses definitive chemoradiotherapy for stage II-IVA disease #hncsm #JCO https://fal.cn/3cQz2 https://fal.cn/3cQz2"  
[X Link](https://x.com/JCO_ASCO/status/1351681858141093888)  2021-01-20T00:04Z 55.4K followers, [--] engagements


"Top [--] questions you should discuss with your statistician when designing dose-finding phase [--] trials #JCOPO https://fal.cn/3dCkO https://fal.cn/3dCkO"  
[X Link](https://x.com/JCO_ASCO/status/1364691332523032583)  2021-02-24T21:39Z 55.4K followers, [--] engagements


"Primary tumor resection followed by chemotherapy in patients with metastatic colorectal cancer doesn't improve survival over chemotherapy alone @JCOG_official #crcsm #JCO https://fal.cn/3dOjs https://fal.cn/3dOjs"  
[X Link](https://x.com/JCO_ASCO/status/1367837397019398148)  2021-03-05T14:00Z 55.4K followers, [---] engagements


"In first-line treatment for metastatic NSCLC adding ipilimumab to pembrolizumab does not improve efficacy Results from KEYNOTE-598 #JCO #lcmsm #immunoonc https://fal.cn/3dRWR https://fal.cn/3dRWR"  
[X Link](https://x.com/JCO_ASCO/status/1369084532373286912)  2021-03-09T00:36Z 55.4K followers, [--] engagements


"Entrectinib demonstrated high overall & intracranial response rates in ROS1 fusion-positive NSCLC in this updated analysis of [--] trials highlighting the need to systematically screen for ROS1 #lcsm #JCO @barlesi @GustaveRoussy https://fal.cn/3ebTG https://fal.cn/3ebTG"  
[X Link](https://x.com/JCO_ASCO/status/1374038672711020545)  2021-03-22T16:42Z 55.4K followers, [--] engagements


"Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden -- results from the @ASCO Targeted Agent and Profiling Utilization Registry (TAPUR) study #JCO https://fal.cn/3eMfB https://fal.cn/3eMfB"  
[X Link](https://x.com/JCO_ASCO/status/1383164055112847365)  2021-04-16T21:03Z 55.4K followers, [--] engagements


"Clinical Review: Multidisciplinary management of locally advanced rectal cancer #JCOOP https://fal.cn/3ffRv https://fal.cn/3ffRv"  
[X Link](https://x.com/JCO_ASCO/status/1391390004442718211)  2021-05-09T13:50Z 55.4K followers, [---] engagements


"HIPEC with carboplatin during secondary cytoreductive surgery in women with recurrent ovarian cancer did not improve outcomes #JCO #gyncsm @ROCearbhaill @zivanovicmd @TeamOvary_MSK https://fal.cn/3fIXK https://fal.cn/3fIXK"  
[X Link](https://x.com/JCO_ASCO/status/1398647835231391745)  2021-05-29T14:30Z 55.4K followers, [---] engagements


"Cancer immunotherapy in older adults -- how do immunotherapy efficacy toxicity and management differ among older adults #GeriOnc #ImmunoOnc #JCO @CPresGeriOncMD @FabioGomes_Go @ChristinBurd @ravikanesvaran @melisawongmd https://fal.cn/3g1io https://fal.cn/3g1io"  
[X Link](https://x.com/JCO_ASCO/status/1403382374650482694)  2021-06-11T16:03Z 55.4K followers, [---] engagements


"Decision making in older adults with cancer #JCO #GeriOnc @cdumonti @MelissaLoh21 @EnriqueSoto8 @WilliamDale_MD https://fal.cn/3g3Nu https://fal.cn/3g3Nu"  
[X Link](https://x.com/JCO_ASCO/status/1404426405430050818)  2021-06-14T13:12Z 55.4K followers, [--] engagements


"Management of HER2-positive advanced breast cancer with a proposed therapeutic algorithm for drug sequencing @prat_aleix et al #bcsm #JCOOP https://fal.cn/3g4xD https://fal.cn/3g4xD"  
[X Link](https://x.com/JCO_ASCO/status/1404507187393744901)  2021-06-14T18:33Z 55.4K followers, [---] engagements


"Convergence of geriatrics and palliative care principles help enhance the care of older adults with cancer #GeriOnc #PallOnc #JCO @RyanNipp @MGHCancerCenter @IshwariaMD https://fal.cn/3g6Cp https://fal.cn/3g6Cp"  
[X Link](https://x.com/JCO_ASCO/status/1404852465066037253)  2021-06-15T17:25Z 55.4K followers, [--] engagements


"#JCO's [----] impact factor increased to [------] which is the highest among oncology publications and in the top 1% of all journals. https://fal.cn/3gsVk https://fal.cn/3gsVk"  
[X Link](https://x.com/JCO_ASCO/status/1410328547504365575)  2021-06-30T20:05Z 55.4K followers, [---] engagements


"CHRYSALIS Phase [--] Study: Amivantamab (EGFR-MET bispecific antibody) yielded durable responses in EGFR Exon [--] insertion-mutated non-small cell #lungcancer after progression on platinum chemotherapy #JCO #LCSM https://fal.cn/3hihK https://fal.cn/3hihK"  
[X Link](https://x.com/JCO_ASCO/status/1424109353297227781)  2021-08-07T20:45Z 55.4K followers, [--] engagements


"Across all tumor types patients with solid tumors treated with #checkpointInhibitors #immunotherapy with good performance status (ECOG 0-1) had superior survival than those with ECOG [--] (median survival [----] vs [---] mo) #JCOOP @MridulaKrishnan https://fal.cn/3ht9W https://fal.cn/3ht9W"  
[X Link](https://x.com/JCO_ASCO/status/1426926668287987716)  2021-08-15T15:20Z 55.4K followers, [--] engagements


"What's the financial burden of meds used to manage common cancer-associated symptoms @guptaarjun90 et al. answer this in a #JCOOP #ASCOQLTY21 simultaneous publication. Read here ➡ #financialtoxicity #supponc @OncoAlert https://fal.cn/3iu0C https://fal.cn/3iu0C"  
[X Link](https://x.com/JCO_ASCO/status/1441483911037661184)  2021-09-24T19:25Z 55.4K followers, [---] engagements


"Fertility preservation counseling is essential to quality cancer care in young pts. @guptaarjun90 discusses the results of a quality improvement project from @hopkinskimmel & @ASCO presented at #ASCOQLTY21 & simultaneously published in #JCOOP here ➡ https://fal.cn/3iuAW https://fal.cn/3iuAW"  
[X Link](https://x.com/JCO_ASCO/status/1441735571395604486)  2021-09-25T12:05Z 55.4K followers, [---] engagements


"Advances in #BreastCancer radiotherapy allow shorter regimens and reduced toxicities. This #JCOOP Clinical review summarizes the latest evidence in #radonc for #bcsm @CshahMD ➡ https://fal.cn/3jsnT https://fal.cn/3jsnT"  
[X Link](https://x.com/JCO_ASCO/status/1454946300726743040)  2021-10-31T23:00Z 55.4K followers, [--] engagements


"Same practice-changing content new look & feel This Twitter page rebranded to our flagship #JCO account. Our other journals now have their own accounts. 📲 Follow us here and at @JCOOP_ASCO @JCOGO_ASCO @JCOPO_ASCO & @JCOCCI_ASCO for the latest in key areas of oncology"  
[X Link](https://x.com/JCO_ASCO/status/1457720831279304709)  2021-11-08T14:45Z 55.4K followers, [--] engagements


"STAMPEDE trial: #QOL was superior w abiraterone acetate/prednisone/prednisolone compared to docetaxel/prednisone/prednisolone inpts w #ProstateCancer ➡ #JCO #PCSM @dr_hanna_rush https://fal.cn/3kqzk https://fal.cn/3kqzk"  
[X Link](https://x.com/JCO_ASCO/status/1467962136123129865)  2021-12-06T21:00Z 55.4K followers, [---] engagements


"TP53 mutations/copy number alterations are potent determinants of response and survival after CD19-CAR-T in large B-Cell. Potential for risk stratification and #clinicaltrial design 👉 #lymphoma #JCO #lymsm @RShouval https://fal.cn/3kHwe https://fal.cn/3kHwe"  
[X Link](https://x.com/JCO_ASCO/status/1471465259584180231)  2021-12-16T13:00Z 55.4K followers, [--] engagements


"👋Sending a warm welcome to Dr. @StephWheelerUNC as she joins #JCO as an associate editor Dr. Wheeler is a prof of health policy & mgmt at @UNCpublichealth & the assoc. director of community outreach & engagement @UNC_Lineberger"  
[X Link](https://x.com/JCO_ASCO/status/1480570276001861633)  2022-01-10T16:00Z 55.4K followers, [---] engagements


"🗒 #JCO #Review: Extensive-stage small cell #LungCancer: first and second-line treatment options #LCSM #sclc @jon_zuga @LuisPaz_Ares https://fal.cn/3lAR7 https://fal.cn/3lAR7"  
[X Link](https://x.com/JCO_ASCO/status/1485756815505829888)  2022-01-24T23:30Z 55.4K followers, [--] engagements


"#FinancialToxicity is Real: Patients with cancer are at higher risk for adverse financial events and past-due credit card bills compared to individuals without cancer 💰 #JCO @ShankaranVeena https://fal.cn/3lFSg https://fal.cn/3lFSg"  
[X Link](https://x.com/JCO_ASCO/status/1486708087608078338)  2022-01-27T14:30Z 55.4K followers, [--] engagements


"No more reformatting Submit your manuscript format-free to @ASCO Journals with EZSubmit ✅ https://fal.cn/3nubO https://fal.cn/3nubO"  
[X Link](https://x.com/JCO_ASCO/status/1510754029432938497)  2022-04-03T23:00Z 55.4K followers, [---] engagements


"A new @ASCOguideline update: Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-risk Early-stage Triple Negative #BreastCancer ➡ #JCO #bcsm https://fal.cn/3nLKz https://fal.cn/3nLKz"  
[X Link](https://x.com/JCO_ASCO/status/1514343935442886665)  2022-04-13T20:45Z 55.4K followers, [---] engagements


"🗣 ZUMA-2 Study: 3-year follow-up of brexucabtagene autoleucel (KTE-X19) in patients with relapsed/refractory #MantleCellLymphoma 🙌 91% objective response 👍 PFS [----] months Read in #JCO: #lymsm @michaelwangmd https://fal.cn/3pFDY https://fal.cn/3pFDY"  
[X Link](https://x.com/JCO_ASCO/status/1539709823708811267)  2022-06-22T20:40Z 55.4K followers, [--] engagements


"🫀 Major adverse #cardiac events with immune checkpoint inhibitors: A pooled analysis of #clinicaltrials sponsored by @theNCI @NCICTEP_ClinRes ➡ #immunotherapy #cardioOnc #immunoonc @thenasheffect @EladSharonMD https://fal.cn/3pFFa https://fal.cn/3pFFa"  
[X Link](https://x.com/JCO_ASCO/status/1539714858026942464)  2022-06-22T21:00Z 55.4K followers, [--] engagements


"@ASCOguideline update published in #JCO by @lynnhenrymd et al: Biomarkers for #SystemicTherapy in Metastatic #BreastCancer ➡ #bcsm #biomarkers @AngieDemichele https://fal.cn/3pNen https://fal.cn/3pNen"  
[X Link](https://x.com/JCO_ASCO/status/1541522516795072515)  2022-06-27T20:43Z 55.4K followers, [--] engagements


"Were pleased to announce our new impact factor of [------] Thank you to our authors and reviewers #JCO #OncTwitter"  
[X Link](https://x.com/JCO_ASCO/status/1541870308218511361)  2022-06-28T19:45Z 55.4K followers, [---] engagements


"🙌 Enfortumab vedotin + pembro as 1st-line tx for metastatic #UrothelialCancer yields response rate of 73.3% duration of response [----] mo overall survival [----] mo.👉 #JCO #blcsm #kcsm #gucsm @DrRosenbergMSK https://fal.cn/3sEjU https://fal.cn/3sEjU"  
[X Link](https://x.com/JCO_ASCO/status/1579931100897427456)  2022-10-11T20:25Z 55.4K followers, [---] engagements


"@ASCO Guideline just published: Treatment of Metastatic Colorectal Cancer Read in #JCO ➡ #crcsm #mCRC https://fal.cn/3sOlo https://fal.cn/3sOlo"  
[X Link](https://x.com/JCO_ASCO/status/1582117915645874176)  2022-10-17T21:14Z 55.4K followers, [---] engagements


"👍 LESS IS MORE - Extra cycles of bevacizumab in frontline maintnenance do not yield improved progression free or overall survival in advanced stage #OvarianCancer 👍 [--] months remains standard of care ➡ #gyncsm https://fal.cn/3u9T5 https://fal.cn/3u9T5"  
[X Link](https://x.com/JCO_ASCO/status/1599448462881349633)  2022-12-04T17:00Z 55.4K followers, [--] engagements


"Just published in #JCO: New @ASCO guideline on #Immunotherapyand#BiomarkerTesting in recurrent and metastatic head and neck cancer https://fal.cn/3ut0z https://fal.cn/3ut0z"  
[X Link](https://x.com/JCO_ASCO/status/1603496884743593994)  2022-12-15T21:07Z 55.4K followers, 29.2K engagements


"🍴 Olanzapine improved appetite and led to weight gain among patients with cancer undergoing #chemotherapy. #JCO #pallonc #supponc ➡ https://fal.cn/3xhpC https://fal.cn/3xhpC"  
[X Link](https://x.com/JCO_ASCO/status/1645539677250756609)  2023-04-10T21:30Z 55.4K followers, 27.1K engagements


"🚬 Smoking cessation after diagnosis of #KidneyCancer is associated with reduced risk of mortality and cancer progression ➡ #JCO #kcsm @mahdi_iarc @IARCWHO https://fal.cn/3xsVr https://fal.cn/3xsVr"  
[X Link](https://x.com/JCO_ASCO/status/1647944273382219776)  2023-04-17T12:45Z 55.4K followers, 13.2K engagements


"🚨 ICYMI: @ASCO #GuidelineUpdate published in #JCO: Initial management of noncastrate advanced recurrent or metastatic #ProstateCancer 👉 #PCSM https://fal.cn/3xDZi https://fal.cn/3xDZi"  
[X Link](https://x.com/JCO_ASCO/status/1650129924512989184)  2023-04-23T13:30Z 55.4K followers, 17.5K engagements


"#ESTRO23 #JCO simultaneous publication by @_ShankarSiva et al: Long-term outcomes of TROG [-----] SAFRON II randomized trial of single versus multi-fraction stereotactic ablative body radiotherapy (SABR) for #pulmonaryoligometastases: https://fal.cn/3yeYX https://fal.cn/3yeYX"  
[X Link](https://x.com/JCO_ASCO/status/1657936345430458368)  2023-05-15T02:30Z 55.4K followers, 15.6K engagements


"🗒 #JCO #Review: Antibody-Drug Conjugates in #LungCancer: Recent Advances and Implementing Strategies➡ #LCSM @peters_solange @APassaroMD https://fal.cn/3zbY7 https://fal.cn/3zbY7"  
[X Link](https://x.com/JCO_ASCO/status/1670404769028923399)  2023-06-18T12:15Z 55.4K followers, 18.1K engagements


"🙌 Germline #EGFR mutations and familial lung cancer 👉 #LungCancer #lcsm https://brnw.ch/21wBDfj https://brnw.ch/21wBDfj"  
[X Link](https://x.com/JCO_ASCO/status/1691087804606877698)  2023-08-14T14:02Z 55.4K followers, 16.9K engagements


"Original research from @CharuAggarwalMD et al. describes how availability of NGS results before 1L therapy for patients with #mNSCLC is associated with better overall survival ➡ #lcsm https://brnw.ch/21wBE4T https://brnw.ch/21wBE4T"  
[X Link](https://x.com/JCO_ASCO/status/1691193034287775744)  2023-08-14T21:00Z 55.4K followers, 14.5K engagements


"🚨 @ASCO #JCO #GuidelineUpdate: Management of Stage III Non Small Cell #LungCancer ➡ #NSCLC #LCSM @ns_chd https://brnw.ch/21wC1fY https://brnw.ch/21wC1fY"  
[X Link](https://x.com/JCO_ASCO/status/1695483499879247960)  2023-08-26T17:09Z 55.4K followers, 13.1K engagements


"🤔 Can the bladder be spared Comparing survival outcomes after surgery vs radical radiotherapy for cN+ #BladderCancer ➡ #blcsm #radonc #surgonc @swinton_martin @achoud72 https://brnw.ch/21wC3Jq https://brnw.ch/21wC3Jq"  
[X Link](https://x.com/JCO_ASCO/status/1696199486362599492)  2023-08-28T16:34Z 55.4K followers, 12.7K engagements


"☢ Molecular analysis of PORTEC-1 & [---] outcomes in #EndometrialCancer demonstrates that molecular classification predicts radiotherapy response 👉 #gyncsm #radonc @NandaHoreweg @LUMC_Leiden https://brnw.ch/21wC66f https://brnw.ch/21wC66f"  
[X Link](https://x.com/JCO_ASCO/status/1696599372333559874)  2023-08-29T19:03Z 55.4K followers, 11.1K engagements


"🧐 In elderly patients w/ RAS/BRAF w/ metastatic #ColorectalCancer panitumumab + FU/LV achieved similar progression-free & overall survival but better safety profile than panitumumab + FOLFOX ➡ #CRCSM #gerionc @sara_lonardi1 https://brnw.ch/21wC8jj https://brnw.ch/21wC8jj"  
[X Link](https://x.com/JCO_ASCO/status/1696934833061036345)  2023-08-30T17:16Z 55.4K followers, [----] engagements


"👏 Ovarian suppression for [--] years improves disease free survival in ER+ #BreastCancer pts after chemotherapy ➡ #BCSM https://brnw.ch/21wDcBN https://brnw.ch/21wDcBN"  
[X Link](https://x.com/JCO_ASCO/status/1709555242386247854)  2023-10-04T13:05Z 55.4K followers, 12.3K engagements


"☢ Stereotactic body #RadiationTherapy and abiraterone acetate achieves biochemical control and improved PFS for patients w/ oligometastatic castrate-resistant #ProstateCancer 👉 #PCSM #radonc @GiulioFrancoli1 https://brnw.ch/21wE3hS https://brnw.ch/21wE3hS"  
[X Link](https://x.com/JCO_ASCO/status/1719707638416429567)  2023-11-01T13:27Z 55.4K followers, [----] engagements


"☢🦴 In a multi-center RCT ⚖ (n=78) radiation to high-risk asymptomatic bone metastases skeletal-related events and prolonged overall survival in metastatic solid tumors: #radonc @ErinGillespieMD https://brnw.ch/21wE43a https://brnw.ch/21wE43a"  
[X Link](https://x.com/JCO_ASCO/status/1719787162802008387)  2023-11-01T18:43Z 55.4K followers, 60.3K engagements


"🤔 #JCO #CommentsAndControversies: It's time to bid farewell to PFS as a primary endpoint in practice-changing trials in advanced cancer ➡ @EAEisenhauer @oncology_bg @ian_tannock https://brnw.ch/21wEmpU https://brnw.ch/21wEmpU"  
[X Link](https://x.com/JCO_ASCO/status/1723349133010870691)  2023-11-11T14:37Z 55.4K followers, 26.8K engagements


"👎 Systemic methotrexate did not reduce CNS progression in high-risk aggressive B-cell #Lymphoma. 👉 #lymsm @Dr_KatLewis @chanyooncheah https://brnw.ch/21wEqUX https://brnw.ch/21wEqUX"  
[X Link](https://x.com/JCO_ASCO/status/1724458443170320760)  2023-11-14T16:05Z 55.4K followers, 10.6K engagements


"New study in JCO shows detectable HPV ctDNA after chemoradiation linked to inferior PFS in patients with HPV+ #CervicalCancer. Testing for HPV ctDNA could flag high recurrence risk early and lead to earlier interventions. Read more: #gyncsm https://brnw.ch/21wEvP9 https://brnw.ch/21wEvP9"  
[X Link](https://x.com/JCO_ASCO/status/1725259975029600396)  2023-11-16T21:10Z 55.4K followers, 17.4K engagements


"🧬 Germline #EGFR mutations and familial #LungCancer ➡ #LCSM #gencsm https://brnw.ch/21wEQux https://brnw.ch/21wEQux"  
[X Link](https://x.com/JCO_ASCO/status/1729607370911744372)  2023-11-28T21:05Z 55.4K followers, [----] engagements


"✨ #JCO #ClinicalTrialUpdates: KEYNOTE-826: First-Line pembrolizumab added to chemotherapy with or without bevacizumab improves overall survival in recurrent/metastatic #CervicalCancer ➡ #gyncsm #ImmunoOnc https://brnw.ch/21wEYWO https://brnw.ch/21wEYWO"  
[X Link](https://x.com/JCO_ASCO/status/1731297506816827644)  2023-12-03T13:01Z 55.4K followers, 22K engagements


"🎤 #OncologyGrandRounds: A comprehensive review and update of the current treatment landscape for platinum-resistant #OvarianCancer. ➡ #gyncsm #ImmunoOnc #ADC @Jstlaurent_MD https://brnw.ch/21wEZjj https://brnw.ch/21wEZjj"  
[X Link](https://x.com/JCO_ASCO/status/1731434157031477701)  2023-12-03T22:04Z 55.4K followers, 10.2K engagements


"✨ #JCO #ClinicalTrialUpdates: COLOPEC: Adjuvant HIPEC did not improve overall or disease-free survival in patients w/ locally advanced #ColorectalCancer. ➡ #CRCSM https://brnw.ch/21wFaPl https://brnw.ch/21wFaPl"  
[X Link](https://x.com/JCO_ASCO/status/1733518402671559102)  2023-12-09T16:06Z 55.4K followers, 44.7K engagements


"Celebrating [--] years of pioneering oncology research with @ASCO's Journal of Clinical Oncology We're thrilled to share this milestone in our history. Look forward to the reveal of our most-cited publication on 12/15. Discover the top-cited articles: https://ascopubs.org/jco/40th-anniversary https://ascopubs.org/jco/40th-anniversary"  
[X Link](https://x.com/JCO_ASCO/status/1734969237523886510)  2023-12-13T16:11Z 55.4K followers, 26.4K engagements


"Celebrating JCO's 40th: Congrats to the #1 most cited #JCO article of the past [--] years 'Gemcitabine For Advanced Pancreas Cancer' by @BurrisSkip et al. (1997). Read the Flashback Foreword by @EileenMOReilly Andrew L. Ko MD @DrJFriedberg 👉 #OncTwitter https://brnw.ch/21wFmYc https://brnw.ch/21wFmYc"  
[X Link](https://x.com/JCO_ASCO/status/1735799812434657644)  2023-12-15T23:11Z 55.4K followers, 120.3K engagements


"🌟🌟🌟 In DESTINY-PanTumor02 Trastuzumab deruxtecan showed durable responses across HER2-expressing solid tumors ➡ #gyncsm #hpbcsm #blcsm @MDAndersonNews https://brnw.ch/21wFvEs https://brnw.ch/21wFvEs"  
[X Link](https://x.com/JCO_ASCO/status/1737831311115763850)  2023-12-21T13:44Z 55.4K followers, 34.1K engagements


"👏 Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial ➡ #PARPi #PCSM @quimmateo https://brnw.ch/21wFyeZ https://brnw.ch/21wFyeZ"  
[X Link](https://x.com/JCO_ASCO/status/1738234718707978712)  2023-12-22T16:27Z 55.4K followers, 11.1K engagements


"🧐 Predictive Value of #MinimalResidualDisease for Efficacy of Rituximab Maintenance in #MantleCellLymphoma: Results From the European Mantle Cell #Lymphoma Elderly Trial ➡ #lymsm #gerionc https://brnw.ch/21wFGT6 https://brnw.ch/21wFGT6"  
[X Link](https://x.com/JCO_ASCO/status/1740801129112330641)  2023-12-29T18:25Z 55.4K followers, 10.5K engagements


"🙌 Osimertinib + chemotherapy enhances CNS efficacy vs osimertinib alone in EGFRm advanced non small-cell #LungCancer ➡ #LCSM @dplanchard https://brnw.ch/21wFOmm https://brnw.ch/21wFOmm"  
[X Link](https://x.com/JCO_ASCO/status/1742955825843351932)  2024-01-04T17:07Z 55.4K followers, 12.1K engagements


"👋 Welcome @MikkaelSekeres #JCOs new Associate Editor for Art of Oncology"  
[X Link](https://x.com/JCO_ASCO/status/1743413347813388739)  2024-01-05T23:25Z 55.4K followers, 13.1K engagements


"At #GI24 👋 Stop by the @ASCO booth to meet with Dr. @PamelaKunzMD the Editor of our newest journal JCO Oncology Advances Learn more about JCO OA: https://ascopubs.org/jcooncologyadvances https://ascopubs.org/jcooncologyadvances"  
[X Link](https://x.com/JCO_ASCO/status/1748075471508840631)  2024-01-18T20:10Z 55.4K followers, 34.4K engagements


"We're excited to announce the launch of JCO Oncology Advances a new journal making cancer research accessible Thrilled to welcome @PamelaKunzMD as Editor-in-Chief leading the charge in bridging science and care. Learn more: #OncTwitter https://brnw.ch/21wGw6h https://brnw.ch/21wGw6h"  
[X Link](https://x.com/JCO_ASCO/status/1752345952134815803)  2024-01-30T15:00Z 55.4K followers, 26.1K engagements


"🔥 D-TORCH study demonstrates 1% topical diclofenac reduces capecitabine-associated hand-foot syndrome (15% v 3.8%) in #BreastCancer and #GastrointestinalCancers ➡ @batraatulmd #supponc #BCSM #CRCSM https://brnw.ch/21wI5h2 https://brnw.ch/21wI5h2"  
[X Link](https://x.com/JCO_ASCO/status/1770797562116653070)  2024-03-21T13:00Z 55.4K followers, [----] engagements


"Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive #ProstateCancer From the Phase III ARANOTE Trial: #pcsm https://brnw.ch/21wN25s https://brnw.ch/21wN25s"  
[X Link](https://x.com/anyuser/status/1838201865277780380)  2024-09-23T13:00Z 55.4K followers, [----] engagements


"Cisplatin once weekly versus every [--] weeks with radiation for locally-advanced head and neck cancer #hncsm http://bit.ly/2Cy1slP http://bit.ly/2Cy1slP"  
[X Link](https://x.com/JCO_ASCO/status/941805183339810816)  2017-12-15T23:00Z 55.4K followers, [---] engagements


"Surveillance versus metastasis-directed therapy for oligometastatic prostate cancer recurrence #pcsm http://bit.ly/2BR7VKX http://bit.ly/2BR7VKX"  
[X Link](https://x.com/JCO_ASCO/status/948192289767264256)  2018-01-02T14:00Z 55.4K followers, [--] engagements


"PSA at [--] months after start of ADT is prognostic in metastatic hormone sensitive prostate cancer #PCSM http://bit.ly/2CcHjnX http://bit.ly/2CcHjnX"  
[X Link](https://x.com/JCO_ASCO/status/948330596815790081)  2018-01-02T23:10Z 55.4K followers, [--] engagements


"Targeted therapy for advanced solid tumors on the basis of molecular profiles - the MyPathway study http://bit.ly/2mFh2ol http://bit.ly/2mFh2ol"  
[X Link](https://x.com/JCO_ASCO/status/954001719389769729)  2018-01-18T14:45Z 55.4K followers, [--] engagements


"Clinical Cancer Care Advances 2018: @ASCO's annual report on progress against cancer http://bit.ly/2EpqGUR http://bit.ly/2EpqGUR"  
[X Link](https://x.com/JCO_ASCO/status/959776013084516353)  2018-02-03T13:10Z 55.4K followers, [--] engagements


"Management of immune-related adverse events from immune checkpoint inhibitor therapy - an @ASCO clinical practice guideline #immunoonc http://bit.ly/2og46He http://bit.ly/2og46He"  
[X Link](https://x.com/JCO_ASCO/status/966384551772741634)  2018-02-21T18:50Z 55.4K followers, [--] engagements


"Chimeric Antigen Receptor T Cells for Cancer Immunotherapy http://bit.ly/2C6aMvF http://bit.ly/2C6aMvF"  
[X Link](https://x.com/JCO_ASCO/status/968585050123132928)  2018-02-27T20:34Z 55.4K followers, [--] engagements


"EML4-ALK variant affects ALK resistance mutations #lcsm http://bit.ly/2He8fCC http://bit.ly/2He8fCC"  
[X Link](https://x.com/JCO_ASCO/status/973240995000315904)  2018-03-12T16:55Z 55.4K followers, [---] engagements


"Understanding the Pathway: Isoform-selective PI3K inhibition in cancer http://bit.ly/2tKekoy http://bit.ly/2tKekoy"  
[X Link](https://x.com/JCO_ASCO/status/974344757597130753)  2018-03-15T18:01Z 55.4K followers, [--] engagements


"Safety of PD-1 inhibitors among patients with NSCLC and preexisting autoimmune disorders #ImmunoOnc #LCSM http://bit.ly/2rOHQ8k http://bit.ly/2rOHQ8k"  
[X Link](https://x.com/JCO_ASCO/status/998551526221238272)  2018-05-21T13:10Z 55.4K followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing